Determination of G1691A mutation in the factor V gene (Leiden mutation)
Material: Blood
Price of the study: PLN 215
Waiting time: result after 5 working days
Booking:
Price of the study: PLN 215
Waiting time: result after 5 working days
Booking:
- Advance appointment booking required by calling 81 532 37 11.
Preparation for the study
General
- The test is taken at a dedicated Intake Point.
- The patient does not need to be fasting.About 30 minutes before the test, it is advisable to drink a glass of water or bitter(unsweetened) tea.
Important
Samples brought from outside are not accepted for testing.
Description
"Determination of the G1691A mutation in the factor V gene (Leiden mutation)
The test involves detecting the presence of the factor V Leiden mutation. The factor V Leiden G1691A gene mutation involves a substitution of a guanine nucleotide for an adenine at position 1691, resulting in resistance of factor V to proteolysis by protein C. This mutation causes an increased risk of thrombophilia (venous thrombosis, arterial thrombosis, myocardial infarction, stroke), recurrent miscarriage and is a major congenital cause of increased risk of thromboembolism. The prevalence of the mutation ranges from 5% to 16% in the general population. The mutation is inherited autosomal dominantly. A person who is a heterozygote of the Leiden mutation has a 5-7 times higher risk of thrombosis than a person without the mutation. Hormonal contraception, cancer, and surgery increase the risk of thrombosis by up to 30 times. A person who is a homozygote of the Leiden mutation has an 80-fold higher risk of"
The test involves detecting the presence of the factor V Leiden mutation. The factor V Leiden G1691A gene mutation involves a substitution of a guanine nucleotide for an adenine at position 1691, resulting in resistance of factor V to proteolysis by protein C. This mutation causes an increased risk of thrombophilia (venous thrombosis, arterial thrombosis, myocardial infarction, stroke), recurrent miscarriage and is a major congenital cause of increased risk of thromboembolism. The prevalence of the mutation ranges from 5% to 16% in the general population. The mutation is inherited autosomal dominantly. A person who is a heterozygote of the Leiden mutation has a 5-7 times higher risk of thrombosis than a person without the mutation. Hormonal contraception, cancer, and surgery increase the risk of thrombosis by up to 30 times. A person who is a homozygote of the Leiden mutation has an 80-fold higher risk of"
Development and preparation of material (applies to contractors only)
1084